Researchers are studying several FDA-approved medications to determine if they can extend human lifespan and improve healthspan [1].
This research is significant because it explores whether existing, approved drugs can be repurposed to slow biological aging and reduce age-related inflammation. If successful, these treatments could move the focus of medicine from treating individual diseases to slowing the aging process itself [1, 3].
Dr. Nir Barzilai, director of the Institute for Aging Research at Albert Einstein College of Medicine in New York, is among the scientists leading these efforts [1]. The research focuses on a group of four FDA-approved drugs highlighted as promising for longevity [1].
A primary area of interest involves GLP-1 receptor agonists [1, 2]. These include semaglutide, known by the brand names Ozempic and Wegovy, as well as tirzepatide, sold as Zepbound [1, 2]. While these medications are widely used for weight loss and diabetes management, researchers are investigating their broader impact on the aging process [2, 3].
Clinical trials and laboratory research are ongoing to evaluate how these substances affect the body's biological clock [1, 2]. The goal is to identify if these drugs can extend the period of life spent in good health, known as healthspan, rather than simply increasing the total number of years lived [1, 3].
The study of these medications is part of a broader scientific push to understand the mechanisms of senescence and cellular decay [3]. By targeting the pathways that lead to age-related decline, researchers hope to mitigate the risks of chronic diseases that typically emerge in older populations [1, 3].
“Researchers are studying several FDA-approved medications to determine if they can extend human lifespan.”
The shift toward repurposing FDA-approved drugs like GLP-1 agonists represents a strategic move in longevity science. By using medications that have already passed safety benchmarks for other conditions, researchers can accelerate the timeline for clinical trials. If these drugs are proven to slow biological aging, it could transition public health strategy from reactive treatment of age-related comorbidities to a proactive, systemic approach to aging.
